Dr. Jun on the Results of a Study Investigating Cyptogenic Hepatocellular Carcinoma

Tomi Jun, MD
Published: Thursday, Jun 22, 2017



Tomi Jun, MD, Stanford University School of Medicine, discusses results of a multi-center study investigating patients with cyptogenic hepatocellular carcinoma (HCC).

It was confirmed in a large cohort of 4000 patients with cyptogenic HCC, that one-third did not have cirrhosis, explains Jun. It was also discovered that this population presents with a later stage of disease and often with more advanced tumors.

According to Jun, this suggests that if there was better early detection, these patients might have better survival rates.
 


Tomi Jun, MD, Stanford University School of Medicine, discusses results of a multi-center study investigating patients with cyptogenic hepatocellular carcinoma (HCC).

It was confirmed in a large cohort of 4000 patients with cyptogenic HCC, that one-third did not have cirrhosis, explains Jun. It was also discovered that this population presents with a later stage of disease and often with more advanced tumors.

According to Jun, this suggests that if there was better early detection, these patients might have better survival rates.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x